StockData
Journey Medical Corp logo

Journey Medical Corp (DERM) stock

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3037% below fair value
$3.69−0.21 (-5.38%)

Close on Nov 18, 2026Market cap $104.15MP/E –Yield –

Journey Medical free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Journey Medical's free cash flow for the twelve months ending Dec 31, 2023 was $240.00K. For fiscal 2024 it was -$24.13M, down 10152.9% from the year before.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$24.13M-10152.9%
FY2023Dec 31, 2023$240.00K–
FY2022Dec 31, 2022-$33.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$16.52M–
Q3 FY2023Sep 30, 2023$18.75M–
Q4 FY2022Dec 31, 2022-$3.84M–
Q3 FY2022Sep 30, 2022-$7.28M–
Q2 FY2022Jun 30, 2022-$3.30M–
Q1 FY2022Mar 31, 2022-$19.12M–

More Journey Medical figures

See a number that looks wrong?